Biomarkers of Acute Lung Injury The Individualized Approach: for Phenotyping, Risk Stratification and Treatment Surveillance.

Abstract

Do we need biomarkers of lung damage and infection: For what purpose and how should they be used properly? Biomarkers of lung damage can be used for diagnosis, risk stratification/prediction, treatment surveillance and adjustment of targeted therapy. Additionally, novel "omics" methods may offer a completely different and effective way of improving the understanding of pathogenesis of lung damage and a way to develop new candidate lung damage biomarkers. In the current review, we give an overview within the field of acute lung damage of (i) disease mechanism biomarkers, (ii) of "ready to use" evidence-based biomarker-guided lung infection management, (iii) of novel strategies of inflammatory phenotyping and how this can be used to tailor corticosteroid treatment, (iv) a future perspective of where "omics" technologies and mindsets may become increasingly important in developing new strategies for treatment and for understanding the development of acute lung damage.

• Authors: Daniel D Murray, Theis Skovsgaard Itenov, Pradeesh Sivapalan, Josefin Viktoria Eklöf, Freja Stæhr Holm, Philipp Schuetz, Jens Ulrik Jensen
• Journal: Journal of clinical medicine (J Clin Med) Vol. 8 Issue 8 (Aug 03 2019) ISSN: 2077-0383 [Print] Switzerland
• PMID: 31382587 (Publication Type: Journal Article, Review)